Publications by NMVB Network Sites 

To Site NMVB please use the following: This work is funded and supported by the Centers for Disease Control and Prevention (CDC) in association with the National Institute for Occupational Safety and Health (NIOSH) Grant, National Mesothelioma Virtual Bank (U24OH009077-013-00). 

For all Publications, please visit our Google Scholar Site.

  1. Simion Chiosea, Alyssa Krasinskas, Philip T Cagle, Kisha A Mitchell, Dani S Zander, Sanja Dacic. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology, 2018 June, 21(6), 742-747.
    Citation: 179
    Journal Impact Factor: 6.365
  2. Assunta De Rienzo, Robert W Cook, Jeff Wilkinson, Corinne E Gustafson, Waqas Amin, Clare E Johnson, Kristen M Oelschlager, Derek J Maetzold, John F Stone, Michael D Feldman, Michael J Becich, Beow Y Yeap, William G Richards, Raphael Bueno. Validation of a gene expression test for mesothelioma prognosis in formalin-fixed parrafin-embedded tissues. The Journal of Molecular Diagnostics, 2017 January, 19(1), 65-71.
    Citation: 9
    Journal Impact Factor: 5.201
  3. Kalyani B Karunakaran, Naveena Yanamala, Gregory Boyce, Madhavi K Ganapathiraju. Mesothelioma Interactome with 367 Novel Protein-Protein Interactions. BioRxiv, 2018 January. Citation: 1
    Journal Impact Factor: 
  4. A Churg, S Dacic, F Galateau-Salle, R Attanoos, M de Perrot, S Dacic. Malignant Mesothelioma In Situ: Clinical and Pathologic Implications. Journal of Thoracic Oncology 2020 June, 15 (6), 899-901.
    Citation: 0
    Journal Impact Factor: 13.357
  5. S Dacic, S Roy, MA Lyons, H Jan, F Galateau-Salle, A Churg. Whole exome sequencing reveals BAP1 somatic abnormalities in mesothelioma in situ.
    Lung Cancer 2020 November, 149, 1-4.
    Citation: 0
    Journal Impact Factor: 4.702
  6. MB Beasley, F Galateau-Salle, S Dacic. Pleural mesothelioma classification update. Virchows Archiv 2021 January, 1-14
    Citation: 0
    Journal Impact Factor: 2.848
  7. M Chevrier, SE Monaco, JA Jerome, F Galateau‐Salle, A Churg, S Dacic. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology. Cancer Cytopathology 2020 December, 128 (12), 939-947.
    Citation: 2
    Journal Impact Factor: 3.818
  8. KB Berg, AM Churg, S Cheung, S Dacic. Usefulness of methylthioadenosine phosphorylase and BRCA‐associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens. Cancer cytopathology 2019 December, 128 (2), 126-132. 
    Citation: 7
    Journal Impact Factor: 3.818
  9. FG Salle, N Le Stang, F Tirode, P Courtiol, AG Nicholson, MS Tsao, S Dacic. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: a multi-institutional study of the International Mesothelioma Panel from the MESOPATH Reference Center.
    Journal of Thoracic Oncology 2020 June, 15 (6), 1037-1053.
    Citation: 7
    Journal Impact Factor: 13.357
  10. S Dacic, N Le Stang, A Husain, B Weynand, MB Beasley, K Butnor. Interobserver variation in the assessment of the sarcomatoid and transitional components in biphasic mesotheliomas. Modern Pathology 2019 July, 33 (2), 255-262.
    Citation: 8
    Journal Impact Factor: 5.988
  11. AG Nicholson, MS Tsao, WD Travis, DT Patil, F Galateau-Salle, M Marino, S Dacic. Staging of thoracic malignancies: implications for the reporting pathologist. Archives of pathology & laboratory medicine 2018 May, 142 (5), 645-661.
    Citation: 12
    Journal Impact Factor: 4.094
  12. S Monaco, M Mehrad, S Dacic. Recent advances in the diagnosis of malignant mesothelioma: focus on approach in challenging cases and in limited tissue and cytologic samples. Advances in anatomic pathology 2018, 25 (1), 24-30.
    Citation: 18
    Journal Impact Factor: 3.746
  13. AM Krasinskas, AC Borczuk, DJ Hartman, JA Chabot, RN Taub, A Mogal, S Dacic. Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma. Histopathology 2016, 68 (5), 729-737.
    Citation: 20
    Journal Impact Factor: 2.021
  14. A Churg, F Galateau-Salle, AC Roden, R Attanoos, H Jan, MS Tsao, S Dacic. Malignant mesothelioma in situ: morphologic features and clinical outcome. Modern Pathology 33 2019 August, (2), 297-302.
    Citation: 24
    Journal Impact Factor: 6.365
  15. AM Marchevsky, N LeStang, K Hiroshima, G Pelosi, R Attanoos, A Churg, S Dacic. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Human pathology 67, 2017 September, 160-168.
    Citation: 29
    Journal Impact Factor: 3.014
  16. DB Chapel, JJ Schulte, K Berg, A Churg, S Dacic, C Fitzpatrick. MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma.
    Modern Pathology 33 2019 June, (2), 245-254.
    Citation: 29
    Journal Impact Factor: 6.365
  17. N Tochigi, R Attanoos, LR Chirieac, TC Allen, PT Cagle, S Dacic. p16 Deletion in Sarcomatoid Tumors of the Lung and Pleura. Archives of Pathology and Laboratory Medicine 2013 May, 137 (5), 632-636.
    Citation: 33
    Journal Impact Factor: 4.151
  18. FG Salle, N Le Stang, AG Nicholson, D Pissaloux, A Churg, S Klebe, S Dacic. New insights on diagnostic reproducibility of biphasic mesotheliomas: a multi-institutional evaluation by the international mesothelioma panel from the MESOPATH reference center. Journal of Thoracic 2018 August, Oncology 13 (8), 1189-1203.
    Citation: 34
    Journal Impact Factor: 32.956
  19. KB Berg, S Dacic, C Miller, S Cheung, A Churg. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesotheliomal Proliferations From Epithelioid Malignant Mesotheliomas. Archives of pathology & laboratory medicine 2018 December, 142 (12), 1549-1553
    Citation: 37
    Journal Impact Factor: 4.151
  20. AG Nicholson, JL Sauter, AK Nowak, HL Kindler, RR Gill, M Remy-Jardin, S Dacic. EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach. Journal of Thoracic Oncology 2020 January, 15 (1), 29-49.
    Citation: 38
    Journal Impact Factor: 13.357
  21. AM Krasinskas, DL Bartlett, K Cieply, S Dacic. CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival. Modern Pathology 201o January, 23 (4), 531-538.
    Citation: 84
    Journal Impact Factor: 6.365
  22. AD Singhi, AM Krasinskas, HA Choudry, DL Bartlett, JF Pingpank, HJ Zeh, S Dacic. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Modern Pathology 2015 October, 29 (1), 14-24.
    Citation: 90
    Journal Impact Factor: 6.365
  23. S Dacic, H Kothmaier, S Land, Y Shuai, I Halbwedl, P Morbini, B Murer. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas. Virchows Archiv 2008 October, 453 (6), 627-635.
    Citation: 101
    Journal Impact Factor: 2.848
  24. S Chiosea, A Krasinskas, PT Cagle, KA Mitchell, DS Zander, S Dacic. Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Modern Pathology 2008 March, 21 (6), 742-747
    Citation: 179
    Journal Impact Factor: 6.365
  25. AN Husain, TV Colby, NG Ordóñez, TC Allen, RL Attanoos, MB Beasley, S Dacic. Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group. Archives of pathology & laboratory medicine. 2018 January, 142 (1), 89-108.
    Citation: 270
    Journal Impact Factor: 4.151
  26. Cummings KJ, Becich MJ, Blackley DJ, Deapen D, Harrison R, Hassan R, Henley SJ, Hesdorffer M, Horton DK, Mazurek JM, Pass HI, Taioli E, Wu X, Zauderer MG, Weissman DN. Workshop summary: Potential usefulness and feasibility of a US National Mesothelioma Registry. American Journal of Industrial Medicine. 2019 November 19. Vol 63(2). https://doi.org/10.1002/ajim.23062
    Citation: 0
    Journal Impact Factor: 1.737
  27. Amin, W, Linkov F, Landsittel DP, Silverstein JC, Becich MJ. Factors influencing malignant mesothelioma survival: a retrospective review of the National Mesothelioma Virtual Bank cohort. F1000Research, 2018 August. DOI: 10.12688/f1000research.15512.1
    Citation: 0
    Journal Impact Factor: 
  28. Hartman, DJ. Borczuk A, Dacic S, Krasinskas A. Reproducibility for histologic parameters in peritoneal mesothelioma. Hum Pathol. 2017 September, 67 54-59. DOI:10.1016/j.humpath.2017.07.005
    Citation: 0
    Journal Impact Factor: 3.014
  29. Amin W, Srinivasan M, Song S, Parwani AV, Becich MJ. Use of Automated Image Analysis in Evaluation of Mesothelioma Tissue Microarray (TMA) from National Mesothelioma Virtual Bank. Pathology Research and Practice. 2014 February, 210(2) 79–82 PMID: 24359722
    Citation: 1
    Journal Impact Factor: 1.13
  30. Amin W, Parwani AV, Melamed J, Raja F, Pennathur A, Valdevieso F, Whelan NB, Landreneau R, Luketich J, Feldman M, Pass HI, Becich MJ. National Mesothelioma Virtual Bank: A Platform for Collaborative Research and Mesothelioma Biobanking Resource to Support Translational Research, Lung Cancer International, vol. 2013, Article ID 765748, 9 pages, 2013. doi:10.1155/2013/765748.
    Citation: 1
    Journal Impact Factor: 0.70
  31. Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I. A Novel Nomogram for Peritoneal Mesothelioma Predicts Survival. Ann Surg Oncol. 2012 Dec 12. PMID:23233234
    Citation: 19
    Journal Impact Factor: 3.930
  32. Wilson RA, Chapman WW, Defries SJ, Becich MJ, Chapman BE. Automated ancillary cancer history classification for mesothelioma patients from free-text clinical reports. J Pathol Inform. 2010 Oct 11;1:24. PMID: 21031012 PMCID: PMC2956176
    Citation: 13
    Journal Impact Factor:
  33. Kang HP, Borromeo CD, Berman JJ, Becich MJ. The tissue microarray OWL schema: An open-source tool for sharing tissue microarray data. J Pathol Inform. 2010 Jul 13;1. pii: 9. PMID:20805954 PMCID: PMC2929536
    Citation: 3
    Journal Impact Factor:
  34. Amin W, Singh H, Pople AK, Winters S, Dhir R, Parwani AV, Becich MJ. A decade of experience in the development and implementation of tissue banking informatics tools for intra and inter-institutional translational research. J Pathol Inform. 2010 Aug 10;1. pii: 12. PMID: 20922029 PMCID: PMC2941965
    Citation: 11
    Journal Impact Factor:
  35. Amin W, Parwani AV, Schmandt L, Mohanty SK, Farhat G, Pople AK, Winters SB, Whelan NB, Schneider AM, Milnes JT, Valdivieso FA, Feldman M, Pass HI, Dhir R, Melamed J, Becich MJ. National Mesothelioma Virtual Bank: a standard based biospecimen and clinical data resource to enhance translational research. BMC Cancer. 2008 Aug 13;8(1):236. PMID:18700971 PMCID: PMC2533341 
    Citation: 35
    Journal Impact Factor: 3.362
  36. Mohanty SK, Mistry AT, Amin W, Parwani AV, Pople AK, Schmandt L, Winters SB, Milliken E, Kim P, Whelan NB, Farhat G, Melamed J, Taioli E, Dhir R, Pass HI, and Becich MJ. The development and deployment of Common Data Elements for tissue banks for translational research in cancer – an emerging standard based approach for the Mesothelioma Virtual Tissue Bank. BMC Cancer. 2008 Apr 8;8:91. PMID: 18397527 PMCID: PMC2329649
    Citation: 45
    Journal Impact Factor: 3.362
  37. Dhir R, Patel AA, Winters S, Bisceglia M, Swanson D, Aamodt R, Becich MJ. A multidisciplinary approach to honest broker services for tissue banks and clinical data: a pragmatic and practical model. Cancer. 2008 Aug 5. PMID: 18683217 PMCID: PMC2745185
    Citation: 55
    Journal Impact Factor: 5.649